expect cystic fibrosi franchis power revenu compound-annual-growth-rate
impli best growth prospect larg cap biotech expect potenti
non-cf pipelin becom clear candid earli clinic
test dcf-base price target increas
top larg cap pick second year
vertex cystic fibrosi franchis continu perform well appear pois drive
industry-lead growth next decad vertex tripl cf regimen
produc impress breakthrough-qu phase result earlier week data
tripl anticip earli vertex file best
perform regimen fda approv impli launch earli
tripl demonstr dramat improv lung function like
extend life expect rapidli broadli adopt base promis
tripl regimen project revenu compound-annual-growth-rate ep
compound-annual-growth-rate highest larg cap biotech patent protect exclus
tripl regimen long lucr commerci live moreov
anticip potenti non-cf pipelin becom clear
least candid earli clinic test larg cap univers
middl growth prospect think fundament posit vertex must
biotech larg cap growth investor expect vertex stock appreci price
target tripl regimen approach commerci launch vertex non-cf pipelin
admittedli vertex unlov investor gener appreci
compani good long-term growth prospect estim less
line consensu howev think sever aspect vertex long-term prospect
underappreci attribut suffici valu first think magnitud
differ revenu growth vertex larg cap peer still fulli
appreci vertex project revenu compound-annual-growth-rate period
comparison averag revenu compound-annual-growth-rate larg cap biotech
celg rang therefor
like first stock benefit generalist growth money return
biotech second success ph trial littl
clinic risk remain project third investor continu debat long-term
prospect competit vertex franchis follow abbv/glpg stumbl
would appear year ahead corrector/potenti regimen
suffici establish domin posit market continu innov
could advanc next gener compound develop extend
lead think unlik competit materi impact estim well
next decad fourth find durabl cf franchis fulli consid
investor initi tripl combin patent protect
commerci life franchis could even longer vertex continu success
innov final non-cf pipelin current ascrib littl valu howev
prospect earli program becom clear least
potenti program pain defici sickl cell disease/beta thalassemia
focal segment glomerulosclerosi earli test
pleas see page report import disclosur
cftr potenti kalydeco standard care cf patient gate partial loss
function mutat also develop regimen contain kalydeco cftr
corrector lumacaftor tezacaftor potenti address cf patient
harbor least one allel orkambi lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
contain gener corrector well tezacaftor ivacaftor produc impress
ph data fda file anticip tripl regimen appear
repres true breakthrough treatment improv qualiti life extend
life span patient model assum cystic fibrosi patient one
vertex therapi drive franchis sale dcf-base price target
initi data ph trial tez/iva
result ph ii
file fda approv first tripl
regimen cf
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
earli
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
past earli
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi orkambi kalydeco standard
therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener posit phase data
tripl combin regimen incorpor second gener corrector
min patient result second tripl regimen contain expect earli
tripl regimen appear repres true breakthrough treatment
improv qualiti life extend life span cystic fibrosi world-wide
moreov patent protect least earli vertex franchis
long commerci life early-stag pipelin includ candid
antitrypsin defici pain sickl cell diseas beta-thalassemia focal segment
next major event vertex cystic fibrosi pipelin releas result
pivot trial tripl regimen
vertex file fda approv one cystic fibrosi tripl regimen
assum prioriti review tripl regimen approv earli possibl
late expect advanc clinic develop
cystic fibrosi candid includ daili ivacaftor well improv next-
gener corrector outsid cystic fibrosi pipelin includ pain
beta thalassemia sickl cell diseas well late-preclin candid
antitrypsin defici focal segment glomerulosclerosi vertex expect
announc proof-of-concept data neuropath pain earli
decis strategi futur develop follow phase i/ii trial
beta thalassemia sickl cell diseas on-going studi singl arm
initi data possibl vertex said candid begin clinic
test late earli possibl initi proof-of-concept data could
avail end vertex also suggest lead focal segment
glomerulosclerosi candid could also enter clinic chang proteinuria
verifi biomark diseas manag note proof-of-concept could
valu vertex use discount cash flow analysi briefli analysi assum
vertex cystic fibrosi franchis grow low-to-mid
singl digit percent revenu growth annual year assum franchis
maintain exclus revenu termin valu thereaft assum
revenu pipelin program outsid cystic fibrosi ph data
de-risk program modestli decreas discount rate assum
dcf increas price target
promin bear case center vertex valuat fact expect
cystic fibrosi franchis high vertex trade project non-
gaap ep bear argu much success tripl revenu growth
alreadi price share earli launch tripl disappoint
would meaning downsid clearli outperform launch
tripl disappoint consult consid tripl regimen major
improv standard care cf patient anticip rapid
adopt bear also note investor assum high penetr
cf market candid assum approxim
address patient one therapi therefor competitor
emerg competit product capabl take minor share
could risk estim think lead time market allow establish
entrench posit would challeng clearli superior regimen
vertex leader discoveri develop candid treat cystic
fibrosi vertex first cystic fibrosi commerci product kalydeco
cftr potenti compound kalydeco approv fda januari
patient gate mutat mutat addit
residu function mutat subsequ ad label seri
supplement approv estim kalydeco achiev
world-wide sale patient gate defect
partial loss function cftr mutat vertex also develop regimen contain
kalydeco ivacaftor cftr corrector lumacaftor tezacaftor potenti
address cf patient harbor least one allel orkambi
lumacaftor ivacaftor succeed two pivot trial june approv
 juli symdeko tezacaftor ivacaftor produc posit data two
phase trial march approv fda februari ema
novemb expect orkambi symdeko wide adopt
cystic fibrosi patient homozyg mutat world-wide improv
potenc orkambi symdeko homozygot effect
patient one copi allel vertex advanc second
gener corrector clinic develop act synergist
lumacaftor tezacaftor complet correct fold defect
cftr tripl combin contain tezacaftor ivacaftor one four second
gener corrector produc impress phase ii proof-of-concept data
tripl combin produc impress phase
data novemb untreat het min patient vx-
regimen produc percentag point improv
homozyg patient addit tez/iva produc
increment percentag point improv result second tripl regimen
contain anticip vertex expect file fda approv
one tripl regimen impli late earli launch tripl
regimen appear repres true breakthrough treatment like improv
qualiti life extend life span patient cystic fibrosi
world-wide moreov second gener corrector patent protect
least earli vertex franchis long commerci life model
assum cystic fibrosi patient one vertex therapi
drive franchis sale dcf-base price target
vertex leader discoveri develop therapi treat cystic fibrosi
vertex focus novel agent modul function cftr
transmembran receptor mutat cystic fibrosi patient best
vertex agent shown produc dramat improv lung function
would expect improv qualiti life lengthen lifespan
cystic fibrosi patient
kalydeco ivacaftor cystic fibrosi transmembran regul compound
first cftr-direct therapi develop launch base strong phase data
fda ema approv kalydeco cf patient age
mutat class gate mutat consult consid kalydeco
true breakthrough improv qualiti patient live like
produc meaning improv lifespan kalydeco fulli
penetr address market patient mutat
eu subsequ label expans extend kalydeco indic gate
partial loss function mutat anticip kalydeco monotherapi could
eventu use gate defect partial loss function
patient project sale
vertex next develop regimen treat broader group patient orkambi
ivacaftor lumacaftor succeed pivot traffic transport phase
trial homozyg patient shown improv percent
predict forc expiratori volum one second well reduc pulmonari
exacerb event requir hospit fda approv orkambi use
homozygot approxim cf patient juli although
orkambi launch fell short expect initi quarter recent perform
solid label expand new territori approv nonetheless
orkambi efficaci somewhat modest certain toler issu
therefor leav room improv combin tezacaftor ivacaftor
symdeko succeed two phase trial march symdeko fda approv
februari licens ema novemb symdeko better
toler modestli better efficaci compar orkambi therefor
help improv complianc persist penetr franchis
investor attent turn combin ivacaftor tezacaftor second-
gener cftr corrector even better efficaci
homozygot well extend use patient world-wide one
copi mutat one copi mutat respond
kalydeco corrector het-min patient tripl combin vx-
produc impress phase data novemb
untreat het min patient regimen produc
percentag point improv homozyg patient
addit tez/iva produc increment percentag point
improv data one vertex tripl regimen like first
regimen treat cftr dysfunct patient major unmet need
treatment today patient repres
cf patient popul homozyg patient tripl regimen also appear
major advanc orkambi symdeko
tripl produc mean absolut improv percentag point
ad top tezacaftor ivacaftor shown improv
approxim percentag point
put efficaci result perspect kalydeco produc approxim
percentag point improv pivot trial patient
week consult consid kalydeco true breakthrough therapi
dramat improv qualiti life like significantli lengthen
lifespan patient therefor think tripl regimen ph data strongli
suggest regimen similar breakthrough cf patient
one copi mutat vertex expect file initi fda approv
base efficaci safeti data impli late
earli launch first tripl like
think pivot data produc tripl
regimen like illumin path revenu growth vertex model
assum cystic fibrosi patient one vertex therapi
drive franchis sale suggest major diagnos cystic
fibrosi patient world-wide one vertex agent moreov project
vertex industry-high revenu growth ep compound-annual-growth-rate
period impli fastest grow larg cap
period expect vertex stock outperform next month
cystic fibrosi portfolio drive industry-lead revenu ep growth
cowen compani
cystic fibrosi rare genet diseas caus mutat cystic fibrosi
transmembran conduct regul cftr base popul genet
consult estim approxim cystic fibrosi patient
 world-wide figur support cf patient north
american cystic fibrosi nacf registri diseas common caucasian
preval area popul european australian descent
today vast major diagnos made upon newborn screen
condit allow earlier intervent treatment
cystic fibrosi chronic progress diseas affect mani bodi system
promin lung digest system although recent therapeut advanc
improv life expect cf remain incur patient expect life span
well normal mani surviv third fourth decad fact
median age death unit state moreov cf patient
significantli impair qualiti life symptom vari patient patient
wax wane time patient nonetheless certain
characterist symptom diseas affect respiratori
digest system lung diseas typic main caus diseas progress
morbid defect function cftr protein result abnorm transport
chlorid ion across cell membran transport chlorid ion requir
effect hydrat epitheli surfac patient cystic fibrosi typic
thick sticki mucu lung clog bronchiol lung lead
frequent lung infect respiratori symptom includ persist cough
produc thick sputum mucu wheez breathless decreas abil
exercis lung transplant common cf patient ultim die
thick mucu also block passag digest enzym pancrea
small intestin prevent adequ absorpt nutrient food mani cf
patient poor weight gain growth sever constip potenti
intestin blockag particularli newborn patient cf due
class iv class cftr mutat typic pancreat insuffici
cftr gene encod multi-domain membran protein atp-bind cassett
transport class superfamili cftr two membrane-span domain four
cytosol loop three cytosol domain includ regulatori domain two
nucleotid bind domain individu carri two copi defect cftr gene
affect diseas peopl one normal one defect copi
call carrier typic unaffect show symptom
known mutat cftr gene five class mutat
cftr caus cystic fibrosi absenc function cftr due defect protein
translat class absenc function cftr due protein fold class ii
defect channel regul class defect cftr channel class iv reduc
cftr function synthesi class class sever
caus case cf class iv mild mutat
caus small minor cf case
common class ii traffick mutat affect
approxim cystic fibrosi patient approxim cystic
fibrosi patient homozyg allel
heterozyg class mutat includ mutat gate
mutat conduct consult estim approxim cystic fibrosi
patient collect rare class mutat total
affect cystic fibrosi patient popul
medic address underli diseas aim re-establish proper chlorid flow
insid lung organ cftr modul three type
cftr modul potenti corrector amplifi potenti hold cftr
protein open allow increas chlorid flow corrector help cftr protein
form correct shape allow proper movement traffick cell
surfac amplifi increas amount cftr protein cell make next-gener
corrector aim improv cftr fold increas amount cftr traffick
cell surfac use drug combin potenti amplifi
improv clinic outcom
antibiot clear infect lung vertex kalydeco first drug
address underli caus cf diseas kalydeco ivacaftor cftr potenti
design restor flow ion activ cftr increas
channel open probabl kalydeco develop use class patient
although first approv use patient kalydeco label sinc
supplement sever time includ number class mutat non-
gate mutat ad eu label
mutat also ad label decemb fda approv
kalydeco addit residu function mutat may five
august full list cftr gene mutat indic kalydeco label
follow chart
list cftr gene mutat produc cftr protein respons kalydeco
phase kalydeco produc mean absolut improv lung function
baselin compar placebo week patient
kalydeco also show impress highli statist signific improv
secondari endpoint compar placebo patient patient receiv kalydeco
less like pulmonari exacerb addit patient gain
lb sign health cystic fibrosi patient kalydeco safe well
toler advers event greater among treat kalydeco
headach upper respiratori tract infect nasal congest rash dizzi
bacteria sputum howev caus patient discontinu
therapi discontinu week due advers event actual less
frequent kalydeco group compar placebo compar
consult enthusiast kalydeco suggest true breakthrough
treatment physician consult believ kalydeco mechan make
perfect sens patient class mutat repres life-alt
therapi side effect kalydeco quickli adopt patient class
mutat approxim cf patient physician say impact
kalydeco clinic practic clinic studi patient
experienc mark improv much weight gain notic better
qualiti life note patient kalydeco feel better within day week
effect dramat kalydeco safe well toler
long term use given kalydeco impact patient physician anticip kalydeco
ultim increas lifespan
cowen compani kalydeco packag insert
kalydeco record revenu vertex believ nearli patient
on-label eu start kalydeco highlight enthusiasm
among patient access kalydeco also impli new territori and/or indic
patient popul requir growth kalydeco
estim respect
use potenti expect improv lung function patient
class mutat strategi less well suit cftr mutat limit
amount function protein cell surfac strategi treat patient
class ii mutat limit amount protein cell surfac combin
cftr corrector cftr potenti corrector molecul design overcom
defect protein process class ii mutat restor proper fold
cftr therebi increas cftr level cell surfac cell surfac
cftr potenti induc cftr work effici possibl strategi
implement patient mutat
vertex move six corrector clinic develop lumacaftor tezacaftor vx-
lumacaftor tezacaftor first-gener
corrector act upon site cftr vx-
second gener corrector interact complementari site
improv fold cftr lumacaftor combin ivacaftor
complet phase trial homozyg patient launch
combin pill call orkambi tezacaftor combin ivacaftor gener
posit phase data homozyg residu function patient
combin approv launch brand name
symdeko europ brand name symkevi three drug combin
tripl combo ivacaftor tezacaftor
gener posit phase ii data het/min homozyg patient first
phase result tripl regimen releas novemb untreat
het min patient regimen produc percentag
point improv homozyg patient addit vx-
tez/iva produc increment percentag point improv result
second tripl regimen contain anticip vertex expect
file fda approv one tripl regimen impli late earli
trial traffic transport combin lumacaftor ivacaftor
cystic fibrosi patient harbor mutat enrol approxim
cystic fibrosi patient age older homozyg
mutat cftr patient predict baselin
random one three arm qd lumacaftor bid
ivacaftor bid lumacaftor bid ivacaftor placebo fix dose
tablet lumacaftor ivacaftor use primari endpoint studi
absolut improv lung function percent predict week
treatment compar placebo secondari endpoint includ rel improv
chang bodi mass index weight gain number pulmonari
exacerb improv patient report outcom follow first
week patient elig double-blind extens studi patient
receiv one combin regimen addit week
june vertex releas strong data traffic transport trial
four treatment arm achiev primari endpoint mean absolut improv
compar placebo produc improv rang
percentag point similarli patient treatment arm experienc
mean rel improv percentag point
pool analysi phase trial proport patient experienc
rel improv cours studi increas
placebo group
treatment group respect addit number pulmonari exacerb
reduc lum qd dose
lum group patient therapi also experienc statist signific
increas compar placebo
past consult said event requir hospit
particularli import endpoint lum qd dose reduc hospit
lum dose patient report
respiratori symptom cfq-r show direct improv
therapi compar placebo howev signific treatment
effect qd lumacaftor group
combin appear reason well toler combo patient
discontinu therapi due advers event patient total compar
placebo patient patient patient kalydeco liver function abnorm
classifi seriou advers event though case elev transient
level return baselin
juli fda approv orkambi use homozygot label
includ homozyg patient age label expand
august includ children age vertex launch orkambi wac
wac increas juli assum
gross net discount complianc rate yield net revenu
per patient vertex reimburs also achiev
australia austria denmark germani ireland itali sweden netherland
speed orkambi adopt peak penetr subject debat
among investor initi quarter orkambi launch fell short project
time orkambi approv expect high rapid launch
initi approv kalydeco penetr address patient within
quarter launch similarli despit consid orkambi efficaci modest
orkambi launch physician consult repeatedli indic anticip
prescrib combin vast major patient reimburs
could obtain physician report advanc approv clinic
prepar onslaught appoint request result physician thought
combin would rapidli achiev peak penetr major physician
survey therapeut confer octob expect
homozyg patient would prescrib orkambi end
unfortun orkambi launch quit live expect penetr
complianc persist initi fall short project vertex disclos
patient start orkambi follow juli launch
increas patient start patient
orkambi launch label compar model estim patient
orkambi juli vertex estim patient
initi orkambi product larg fulli penetr exist
fall short project orkambi wide adopt nonetheless
conduct cystic fibrosi survey advanc march
confer survey physician indic homozyg cf
patient age prescrib vertex orkambi panelist
report pediatr cf practic orkambi indic
parent children appear healthi reluct start children chronic
therapi despit belief earli pre-symptomat intervent like lead
superior long-term outcom adult cf patient symptom report
adult tri orkambi survey physician report
patient start orkambi discontinu panelist indic
primari reason discontinu chest tight side effect orkambi
common/burdensom patient sever lung dysfunct time
start therapi practic focus pediatr cf rare problem
patient discontinu occur howev adult cf colleagu
report discontinu occur patient could explain
bimod distribut survey respons
cowen compani confer
cowen compani confer
reimburs orkambi outsid progress fit start
follow ema approv orkambi novemb austria becam first
countri final reimburs juli follow germani decemb
sweden june australia septemb notabl countri
yet final reimburs agreement includ uk franc
final german price agre decemb believ
uptak slow elig german patient drug
first year convers uptak franc via atu brisk
elig patient orkambi even though final
reimburs secur revenu recognit rule requir vertex
recogn atu sale albeit low price begin though vertex
cancel french phase trial site tripl regimen februari site
reactiv howev unclear vertex franc abl
agre upon price orkambi
juli austria becam first countri final orkambi reimburs
patient agreement went effect septemb price
disclos agreement includ requir patient test
everi month must discontinu orkambi best therapi
prior year best valu chang number
pulmonari exacerb observ
april vertex irish health ministri announc two parti
reach agreement principl vertex reimburs orkambi
homozyg patient age well reimburs kalydeco
patient age minist also disclos contract negoti
broaden includ treatment cf patient cf ireland report
understand contract also includ coverag adult cf patient
mutat rapid access new drug combin label expans
approv patient previous cover cf mutat gate
mutat vertex guid irish homozyg popul
patient although irish press report state deal encompass patient
perhap least differ reflect pediatr kalydeco patient
govern offici report initi vertex price submiss ask orkambi
reimburs final price negoti lower
though final price disclos irish press also report
price agreement cover year
patient april indic follow-up data would requir
order obtain reimburs approv traffic transport extens
data present nacfc april danish author approv orkambi
reimburs certain cf patient agreement homozyg
patient year old adult children
elig treatment patient may also qualifi therapi meet two
follow criteria adult children suffer
declin past month chronic multiply-resist infect
adult z-score children therapi
patient requir revalu diseas statu everi month
medic council reassess continu elig therapi everi month
danish govern price databas indic vertex maintain
krone price follow agreement
vertex also reach reimburs agreement italian author
agreement orkambi reimburs began june
homozyg patient age least year old vertex believ enabl
patient receiv orkambi italian govern disclos orkambi
reimburs price per day suppli
total italian spend cap first calendar year vertex
guid penetr complianc persist orkambi long
term appli metric italian contract would impli effect
price
dutch reimburs began novemb vertex estim
indic orkambi price per day suppli
assum penetr complianc would indic dutch
market opportun
june vertex swedish health author agre long-term access
agreement allow reimburs orkambi homozyg
cf patient start juli addit agreement includ framework
assess grant access vertex futur cf medicin swedish
govern estim patient elig orkambi
reimburs approv territori appear progress fit
start spain gcpt submit review orkambi dgcsf may
therefor believ formal spanish patient price negoti
way may belgian author announc unabl reach
agreement vertex therefor end negoti
canadian approv grant januari label expand includ
patient age april june canadian drug expert committe
cdec reject vertex initi reimburs submiss vertex request
grant reconsider cdec octob meet reimburs
reject novemb vertex made new submiss includ two-
year extens data traffic/transport howev also reject
cdec februari reject cdec state would accept data
come random trial consequ march british columbia
quebec health author announc orkambi exclud
australian regulatori submiss approv march april
australia pbac reject vertex applic orkambi reimburs cite need
long-term lung function surviv data second third fourth vertex
submiss pbac reject decemb april juli
fifth final submiss cover patient age consid juli
pbac meet submiss success septemb vertex
announc final agreement australian govern allow
reimburs orkambi homozyg patient age six
begin octob vertex estim approxim patient
australia elig treatment orkambi
despit protract negoti vertex hope countri
ultim reimburs orkambi symdeko tripl regimen particular
manag continu optimist path reimburs uk
franc
vertex note number countri base reimburs decis health
econom model incorpor paramet cost therapi longev
product hospitalizations/futur healthcar cost vertex suggest
countri initi assumpt often conserv use clinic
experi adjust paramet econom model support price
vertex will accept tripl regimen dramat efficaci
orkambi vertex also think possibl health econom model post-tripl
approv could like support reimburs make negoti
progress smoothli moreov portfolio deal current futur vertex
cf therapi reimburs similar term appeal vertex
countri countri get budget certainti price concess avoid year
reimburs negoti allow product market year
earlier vertex abl realiz cumul revenu better long-term
symdeko combin ivacaftor tezacaftor tezacaftor first-
gener corrector like lumacaftor tezacaftor work
mechan lumacaftor subtl differ tezacaftor differ
tissu distribut also metabol somewhat differ unlik lumacaftor
drug-drug interact ivacaftor vertex conduct broad
pivot program tezacaftor consist phase trial test symdeko
function heterozygot combin tezacaftor
ivacaftor gener posit phase data homozyg residu function
patient fail show benefit het min gate mutat patient vs kalydeco
combin approv fda februari ema
novemb vertex given tezacaftor/ivacaftor fix dose pill brand
name symdeko symkevi eu
march vertex releas posit top-lin data symdeko evolv phase
trial phase studi global random double-blind placebo-control trial
evalu symdeko peopl cf age older two
copi mutat patient random receiv either symdeko
consist tezacaftor qd ivacaftor placebo primari
endpoint trial absolut chang baselin week
secondari endpoint includ rel chang number pulmonari
exacerb week chang bodi mass index chang cfq-r
baselin studi arm week studi
mean absolut improv percentag point baselin
treat symdeko compar placebo comparison orkambi
produc improv percentag point week traffic
transport trial compar baselin patient placebo arm declin
percentag point symdeko improv percentag point
importantli symdeko benefit observ regardless age baselin
concomit use antibiot bronchodil corticosteroid hyperton salin
secondari endpoint analyz use hierarch test procedur symdeko
produc placebo-adjust rel chang percentag point
symdeko also reduc annual rate pulmonari exacerb
per week placebo vs per week symdeko
symdeko produc chang bodi mass index
cfq-r improv symdeko statist
signific cfq-r fell behind analysi hierarchi
symdeko well toler rate respiratori advers event dyspnea abnorm
respir bronchospasm etc reduc placebo patient
symdeko group number patient experienc advers event
placebo vs symdeko seriou advers event placebo
vs symdeko reduc symdeko discontinu due advers event
similar group placebo vs symdeko
februari fda approv symdeko tezacaftor/ivacaftor use cystic
fibrosi patient age either homozyg allel
heterozyg second mutat residu function mutat health
canada follow june ema approv symkevi novemb
 vertex price symdeko wac per day pack
premium orkambi lumacaftor/ivacaftor symdeko label
includ sever favor chang rel label orkambi unlik orkambi
warn respiratori event warn blood pressur
increas precaut hormon contracept reli upon
effect method contracept
orkambi gener global sale project revenu
vertex combin cftr therapi orkambi symdeko tripl etc franchis
respect
physician panelist march confer indic
symdeko primari benefit lack orkambi chest tight ae symdeko also
indic use function patient previous
elig kalydeco physician survey advanc march confer
believ symdeko launch increas use corrector/potenti therapi
panelist agre believ increas primarili come
patient discontinu prior orkambi use due chest tight also
believ patient orkambi hadnt felt obviou improv
diseas also opt tri symdeko vertex price symdeko premium
orkambi therefor switch orkambi would associ modest
increas revenu vertex final panelist report also switch
patient kalydeco symdeko vertex price symdeko discount
kalydeco consequ switcher kalydeco would associ
modest decreas revenu vertex
cowen compani confer
doublet regimen vertex includ ivacaftor lumacaftor tezacaftor
produc kalydeco-lik efficaci homozygot fail
demonstr efficaci het-min patient preclin data suggest
combin singl corrector potenti restor minor cftr
function mutat like caus sub-optimal treatment
respons moreov biophys studi suggest defect cftr
result two separ fold problem cftr protein suggest corrector
two mechan like necessari get suffici amount cftr protein
cell surfac therefor tripl regimen potenti two corrector
consid promis improv efficaci homozyg patient
provid first treatment het-min patient
vertex sought build tripl regimen ivacaftor tezacaftor third agent
potenti potent abil correct cftr defect base
strong preclin data support strategi ad second-gener corrector
vertex advanc four next-gener corrector clinic trial
juli januari april vertex releas
convinc phase ii proof concept data improv
percentag point four next-gener corrector
homozygot and/or het min patient risk mitig purpos vertex decid
conduct phase program tripl regimen contain
tripl produc compel phase data
novemb result phase program vx-
tripl anticip vertex expect file initi
fda approv base efficaci safeti data impli
launch first tripl like
gener compel proof concept data support
data phase ii trial tezacaftor/ivacaftor /- either
het min patient releas januari produc
impress kalydeco-lik chang patient rang
percentag point day lung function improv in-lin
slightli better data previous produc
 moreov produc similar somewhat better reduct sweat
chlorid mmol/l mmol/l compar mmol/l
wherea improv respiratori symptom cfq-r
point improv respiratori symptom much
also appear somewhat safer/bett toler
teratogen signal gi major advers event
mild moder studi treatment relat sae
occur patient discontinu treatment due one patient interrupt
therapi due rash although rash resolv recur treatment
reinstat common cough headach throat pain increas
sputum vertex believ cough sputum fact signal on-target
studi treatment relat sae occur patient discontinu
therapi due rash increas bilirubin compar none placebo
group rash bilirubin resolv treatment discontinu
addit patient interrupt therapi due constip
increas bilirubin resolv treatment resum without
incid importantli case bilirubin associ elev
transaminas clinic symptom also produc
april vertex releas addit phase ii data trial
updat consist data homozyg patient random
receiv placebo week follow week run-in period tez/iva
week treatment patient experienc point improv
compar point improv among placebo treat
patient similarli sweat chlorid declin mmol/l patient
vs mmol/l increas placebo patient final cfq-r patient report
outcom improv point among patient compar point
placebo patient efficaci appear par data previous produc
similar trial improv mmol/l decreas sweat chlorid
point increas cfq-r vertex report tripl regimen gener well
toler safeti consist prior dataset sae report
among patient receiv common includ sputum increas
cough infect pulmonari exacerb liver enzym elev one tripl patient
discontinu therapi due chest pain resolv stop therapi anoth
tripl patient interrupt therapi due myopathi concurr increas alt ast
level resolv patient success resum treatment without
risk mitig purpos vertex advanc two second gener
corrector phase develop januari vertex announc
select advanc base upon phase i/ii dataset
show efficaci least in-lin prior data qd
dose vs bid dose improv safety/toler profil
rel
vertex initi patient phase trial tez/iva /-
homozygot patient phase trial tez/iva vs placebo
het min patient trial util primari efficaci endpoint week
longer follow addit safeti efficaci analys week
beyond posit interim result program releas novemb
manag wish conduct initi phase program conjunct
howev fda seek addit dose data
manag want delay pivot trial thu advanc
phase develop use backbon tez/iva rather
phase trial homozygot het min patient employ
essenti ident trial design trial patient popul
enrol pivot trial complet novemb top-lin
data read
manag expect file fda approv use efficaci
week safeti data trial manag expect also provid fda
updat safeti databas review period use week safeti analys
importantli manag believ chronic natur therapi rapid adopt
curv cf could support market share high littl year
commerci lead time competit altern
prior phase data read-out european regul request
week efficaci data support regulatori submiss howev vertex plan
discuss european regul phase trial
read given extent benefit seen week vertex
hope tripl regimen contain efficaci data
superior could approv base efficaci data earlier time point perhap
data similar
vertex plan decid second gener corrector bring market
phase data avail tripl combin trial earli
submiss nda plan later assum rapid fda
file prioriti review vertex tripl could market end
earli
abbrevi path good min patient current
diseas modifi therapi also confer clear benefit vertex launch
tripl regimen would acceler revenu growth well
rais bar competit pivot program necessari potenti
competitor remain determin regulatori author suspect
head-to-head trial vertex regimen may necessari
novemb vertex announc posit top-lin data pre-specifi interim
analysi two on-going phase studi tripl combin second-
gener cftr corrector first gener cftr corrector tezacaftor cftr
potenti ivacaftor vertex note safeti efficaci profil result
releas today support potenti submiss new drug applic nda
tripl combin regimen impli clinic develop risk
remov vertex tripl program
first phase trial random double-blind placebo-control studi
patient age one mutat one minim function
mutat het-min time analysi patient complet week
visit studi trial primari endpoint treatment vx-
produc mean improv percentag
point week compar tripl placebo mean improv
percentag point baselin week vx-
treat group versu percentag point tripl
placebo group base data patient time interim analysi
includ patient treat week treat week vertex
report tripl regimen gener well toler addit efficaci
safeti data week includ key secondari endpoint report
patient complet treatment week time
interim analysi enter open-label extens studi
second phase trial random double-blind studi patient age
homozyg mutat patient receiv
tezacaftor ivacaftor week run-in period random
receiv either tripl treatment tezacaftor ivacaftor placebo
combin tezacaftor/ivacaftor top-lin data includ result
patient trial primari endpoint treatment produc mean
absolut chang percentag point rel
placebo/tezacaftor/ivacaftor week mean improv
percentag point baselin end run period week
treat group rel percentag point
placebo/tezacaftor/ivacaftor group vertex note gener well
toler addit safeti efficaci data includ key secondari endpoint
present patient complet studi enter
open-label extens
vertex also announc enrol complet two phase
studi tripl combin tezacaftor ivacaftor het min
homozygot top-lin data interim analysi on-track
addit safeti efficaci data plan present
believ data good investor hope confirm vertex
tripl regimen breakthrough treatment het min
homoyg cystic fibrosi patient sens investor expect
produc least percentag point placebo-adjust increas het min
trial investor thought improv would mid-
teen percentag point therefor efficaci result came high end
expect arguabl good investor hope moreov
produc increment percentag point improv ad
tezacaftor/ivacaftor symdeko homozyg patient tripl regimen
also produc dramat efficaci benefit popul orkambi
symdeko current standard care
fact popul tripl regimen produc improv versu
standard care compar perhap even somewhat produc
kalydeco pivot trial untreat patient approxim percentag
point consult consid kalydeco breakthrough treatment patient
cftr gate mutat therefor phase result
believ tripl therapi demonstr level
efficaci dramat improv qualiti life -- like lengthen
lifespan -- cystic fibrosi patient least one allel
approxim cystic fibrosi patient least one allel
includ approxim cf patient het min
current effect safe therapi tripl regimen appear
major advanc cystic fibrosi patient
ph trial complet vertex select best tripl regimen
file regulatori approv therefor remain possibl
commerci nonetheless even better
therefor initi result would appear repres minimum improv
care vertex tripl produc
follow top-lin data read-out vertex choos best regimen
submit regul nda slate submiss base
efficaci safeti data assum rapid fda file prioriti review
vertex tripl could market end earli ex-u
submiss plan late
tripl gener kalydeco-lik efficaci studi thu far appear
similar breakthrough treatment cystic fibrosi kalydeco compel
clinic profil drove rapid adopt mani market larg penetr within
quarter launch moreov kalydeco high persist complianc patient
feel wors dose skip discontinu vertex anticip tripl
penetr persist complianc similar kalydeco
march vertex acquir global right concert deuter
ivacaftor concert could elig addit
regulatori reimburs mileston approv part
combin regimen treat cf grant reimburs
uk germani franc importantli vertex owe concert royalti vx-
vertex manag intrigu potenti preclin
earli clinic data suggest pharmacokinet consist daili dose
manag believ acquisit acceler vertex
develop daili combin regimen cystic fibrosi kalydeco
ivacaftor must dose twice per day candid vertex pipelin
pharmacokinet data consist daili dose includ first gener
corrector tezacaftor second gener corrector
vertex preclin program investig extend releas formul
kalydeco order enabl develop daili combin regimen
howev vertex suggest year behind therefor
acquisit acceler vertex abil introduc daili combin
regimen vertex preclin assay ivacaftor appear equipot
note could also support modestli better gross margin
subject ivacaftor cf foundat royalti
concert previous initi phase ii monotherapi trial gate mutat
patient though vertex plan pursu indic instead vertex rapidli
incorpor triplet develop program
april vertex report first tripl data includ time
data phase ii trial test /- het min
patient releas trial patient receiv
achiev improv point vs point
improv among placebo group similar sweat chlorid vs mmol/l
data also report cfq-r improv point observ
group manag explain two placebo patient outlier cfq-r respons
posit efficaci data also releas trial tezacaftor /-
includ vs sweat chlorid vs cfq-r
contain regimen safe well toler sae report
patient pulmonari exacerb across placebo group compar
patient pyrexia/dyspnea/pleurit pain pulmonari exacerb vx-
tripl tripl group one patient discontinu tripl
combin due rash resolv follow treatment cessat
tripl combin patient interrupt treatment due rash resolv one patient
success reiniti therapi demonstr drug
hypersensit subsequ discontinu treatment manag
believ case rash consist rate report fda label
kalydeco orkambi
vertex convinc once-daili tripl success
demonstr safeti efficaci par twice daili ivacaftor- contain tripl
regimen expect move ph regimen contain
howev discuss fda becom clear fda consid vx-
new chemic entiti fda request addit dose rang studi
includ monotherapi perform prior advanc pivot
dinner host vertex septemb manag note
good understand fda view data must
gener vertex expect initi dose-rang trial monotherapi cf
patient gate mutat
impress data vertex current gener tripl regimen
vertex still think room improv particular manag would
like once-daili regimen allow cf patient similar level cftr
function peopl cf carrier peopl one copi cftr gene
mutat typic develop cystic fibrosi though impress
efficaci two tripl regimen current pivot develop quit return
cftr function level cf carrier requir twice daili dose
deuter ivacaftor half-lif consist daili dose
tezacaftor ivacaftor also once-daili molecul
inclus tripl would allow once-daili dose note previous
vertex expect conduct trial move forward
vertex corrector preclin develop appear capabl produc
carrier-lik cftr function sweat chlorid level incorpor tezacaftor
ivacaftor vertex hope begin clinic develop first
think like proof concept data gener
first tripl avail market world-wide
produc impress efficaci phase
program vertex clearli establish proof-of-concept abil tripl regimen
expand cftr target therapi patient improv efficaci
cftr target therapi homozyg patient patient
tripl regimen produc improv percent
predict percentag point therefor tripl regimen
like first therapi treat cftr dysfunct patient
major unmet need treatment today patient
repres cf patient popul homozyg patient tripl
regimen also appear major advanc orkambi symdeko vx-
tripl produc mean absolut improv
percentag point ad top tezacaftor ivacaftor
shown improv approxim percentag point regimen
appear gener well toler put efficaci result perspect
kalydeco produc percentag point improv pivot trial
patient consult consid kalydeco true breakthrough therapi
dramat improv qualiti life like significantli lengthen
lifespan patient past ph ii data cftr modul
predict long term benefit therefor think compel
phase data tripl strongli suggest
regimen similar breakthrough cf patient one copi
base compel clinic profil kalydeco high penetr persist
complianc cf patient label popul strong
clinic data expect tripl regimen similar adopt among
cf patient least one copi mutat moreov second
gener corrector patent protect earli extend
commerci life vertex franchis year vertex cftr franchis gener
global sale model franchis sale
respect
cowen compani
statesnumb patient diagnos patient penetr patient per patient patient gate gate penetr patient per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
former partner galapago collabor creat tripl regimen compet
vertex cystic fibrosi compani portfolio includ potenti
first-gener corrector
second-gener corrector result
abbvie/galapago first tripl regimen releas octob
appear competit vertex fact said advanc
current clinic candid pivot test instead look innov preclin
candid achiev carrier-lik cftr function compet vertex next
gener candid initi stumbl vertex benefit give vertex
increas lead time market least likelihood
competit tripl decreas also lessen investor concern
near- intermediate-term competit vertex cf franchis
galapago test efficaci second gener corrector pelican trial
trial enrol homozyg patient stabl orkambi
least week prior first studi drug administr patient random
add-on placebo week patient requir continu
orkambi durat trial random receiv
placebo period week week follow-up primari
endpoint trial chang baselin sweat chlorid concentr
compar placebo day
june galapago announc trial met primari endpoint
mean chang baselin sweat chlorid treatment arm day
versu placebo mmol/l also posit trend
reach statist signific lung function mean absolut chang
baselin treatment arm versu placebo day
appear safe well toler trial advers
event mild moder differ incid compar placebo
death seriou advers event prematur discontinu
due advers event
abbvie/galapago also conduct falcon trial tripl combin
potenti corrector corrector
falcon trial homozyg patient enrol receiv
week follow week result releas
octob doublet increas sweat chlorid
mmol/l subsequ two week treatment tripl regimen
increas sweat chlorid
improv sweat chlorid top symdeko
initi tripl appear competit lead tripl fall well short
seemingli need better potenti corrector remain skeptic
program threat
proteostasi use disease-relev translat drt platform identifi novel drug
candid impact protein homeostasi use drt platform proteostasi
advanc wholli own cftr corrector potenti amplifi
clinic develop proteostasi expect releas initi tripl
combin data
preclin data present ecf data indic
ad ivacaftor produc greater increas chlorid
transport lumacaftor administ top ivacaftor proteostasi
cftr amplifi proteostasi releas initi data day phase trial
orkambi decemb patient complet day
qd treatment manag report patient experienc mean
absolut improv percentag point baselin
june proteostasi announc posit result phase studi
orkambi patient background orkambi patient
concurr receiv escal dose
placebo higher dose orkambi produc
mmol/l decreas mmol/l decreas sweat
chlorid dose respect signific chang
dose dose orkambi produc
decreas vs baselin comparison chang observ
also statist signific chang measur
orkambi group common pulmonari exacerb
regardless treatment group addit patient may enrol
highest dose result anticip
proteostasi potenti also complet phase develop
manag report healthi volunt dose one patient
experienc sae relat transvers myeliti consid drug relat
mild-moder manag also believ pk support qd
phase studi orkambi
cftr mutat mutat result cftr protein misfold
misfold detect cell machineri much protein direct
destruct howev cftr protein degrad small fraction
ultim make cell surfac also retain low level activ
proteostasi develop cftr amplifi design stabil
interact cftr mrna ribosom endoplasm reticulum
therebi increas rate cftr protein produc overal increas
cftr protein also increas amount protein make cell
surfac importantli approach synergist corrector
proteostasi conduct phase i/ii trial includ singl ascend dose
cohort follow multipl dose cohort
monotherapi top orkambi final phase ii expans cohort
orkambi proteostasi present phase multipl dose data trial
nacfc nasal sampl obtain patient indic treat patient
fold increas cftr protein vs baselin pk data indic signific
ddi orkambi activ ingredi lumacaftor ivacaftor top-
line data phase ii portion trial releas decemb
portion trial patient background orkambi enrol receiv pti-
qd placebo treat patient experienc mean
absolut improv vs placebo sae observ
patient orkambi alon discontinu therapi
due thrombocytopenia march fda grant breakthrough therapi
design base phase ii result orkambi
doublet improv lung function decreas sweat chlorid
octob proteostasi announc result phase trial test doublet
therapi cftr transmembran conduct regul cftr
potenti time data cut subject random
treat first three dose cohort doublet combin
placebo
compound well toler pulmonari exacerb report
dose follow period studi
doublet produc dose-depend sweat chlorid concentr
increas baselin day day compar placebo
differ day day
doublet produc mmol/l decreas sweat chlorid concentr
day day data highest dose cohort pti-
anticip
pti also conduct separ studi cf subject
background symdeko therapi studi underway expect produc
data
decemb proteostasi disclos phase healthi volunt dose pti-
complet subject manag report
signific ddi observ combin well toler dose
day led studi discontinu proteostasi began dose cf
patient tripl regimen plan report initi data
complet data doublet triplet cohort expect
vertex establish corpor goal develop function cure cftr function
equival carrier statu cf patient kaydeco tripl regimen
approach goal mani patient vertex believ novel approach
need increas efficaci and/or expand efficaci minor cf
patient produc viabl protein upon correctors/potenti act
end vertex struck partnership agreement
therapeut parion scienc
corrector potenti therapi design restor function otherwis
dysfunct cftr protein result myriad cf mutat logic
altern approach would introduc wild-typ cftr cell vertex two
collabor direct achiev goal
juli vertex announc partnership aim
deliv function copi cftr mrna patient cftr mutat vertex
made up-front payment convert note invest
partnership success could receiv
develop regulatori mileston approv reimburs
mileston tier royalti
octob vertex announc partnership
partnership merg vertex knowledg rare diseas develop crispr
base gene edit technolog gener potenti gene edit
therapi cystic fibrosi sickl cell diseas rare genet disord vertex
entitl option six potenti therapi partnership vertex
made up-front payment equiti invest
among larg cap biotechnolog compani vertex set apart compani
competit product expand market minim competit investor
give vertex full credit creat top-notch cf franchis expect tripl
regimen expand market thu upsid stock depend part
compani abil develop new therapeut candid therapeut area
expand pipelin vertex aim continu intern research antitrypsin
defici sickl cell diseas polycyst kidney diseas focal segment
glomerulosclerosi in-licens addit phase i/ii asset addit vertex
initi trial -thalassemia sickl cell diseas partnership crispr
therapeut neuropath pain phase ii data anticip
decemb vertex partner crispr announc
intent initi clinic develop crispr base gene edit approach
hemoglobinopathi -thalassemia sickl cell diseas
first clinic candid partner collabor agreement partner
agre co-develop co-commerci cta
thalassemia file mhra decemb clinic studi
initi ind sickl cell diseas file fda
may partner announc place clinic
hold prior enrol patient though fda concern lead
hold never disclos hold resolv octob vertex report
first -thalassemia patient enrol sickl cell trial begun
function hemoglobin aris interact -globin either -globin
fetal develop -globin express alongsid high level -globin late
fetal develop earli childhood -globin express replac
globin express therefor -globin becom domin partner -globin
month age defect -globin gene begin present clinic case
thalassemia mutat -globin gene reduc even elimin -globin protein
product sickl cell diseas -globin protein produc mutat caus red
blood cell sickl lead poor oxygen transport pain veno-occlus crise
complic rare case second mutat gene prevent
product normal repress -globin express therefor
absenc -globin express persist adulthood importantli level
persist -globin express correl sever -thalassemia sickl
cell diseas symptom result sever group propos diseas
could effect treat cure increas persist express
vertex/crispr crispr base gene edit approach block
product therebi increas express -globin preclin data
support present partner report
guid rna abl success edit allel hematopoiet
stem cell led coloni achiev bi-allel edit
contain mono-allel edit bi-allel edit cell capabl produc
suffici -globin achiev nearli hbf ratio -globin/ -globin -globin
mono-allel cell abl achiev hbf ratio aggreg led
averag hbf ratio partner believ vivo hbf ratio
suffici prevent sickl
vertex develop inhibitor oral treatment acut
neuropath pain sodium ion channel subtyp express dorsal root
ganglion involv nocicept drug first studi treatment
osteoarthr pain septemb vertex releas data
placebo control phase ii trial patient experienc placebo adjust chang
western ontario mcmaster univers womac osteoarthr index pain
subscal score day manag report frequenc
sever similar placebo patient four
patient discontinu treatment due compar zero placebo patient
vertex also studi drug acut pain follow surgeri februari
vertex report top-lin data phase ii trial acut pain follow
bunionectomi trial enrol patient receiv placebo
hydrocodon acetaminophen primari endpoint time-
weight pain intens differ first hour treatment
record numer pain rate scale npr treat vx-
compar placebo achiev point improv rel
placebo comparison valu hydrocodon acetaminophen
placebo-adjust improv hour
first dose placebo-adjust improv point observ
rel hydrocodon acetaminophen group
perform hour appear compar hydrocodon
acetaminophen vertex report well toler advers event
observ placebo hydrocodon acetaminophen
patient respect discontinu due
placebo control phase ii trial neuropath pain caus
small fiber neuropathi on-going data expect phase iib multipl
ascend dose trial oral formul follow result
inform dose chosen pivot phase trial vertex also plan initi
phase develop iv formul acut pain follow
outcom trial manag decid upon optim develop path
may opt out-licens
follow releas data neuropath pain multipl ascend dose
trial vertex evalu strateg option manag think vertex could
commerci acut pain independ acut pain specialti market
approxim today osteoarthr pain hand mass market
specialti one therefor vertex would like partner develop
commerci oa-rel pain vertex suggest neuropath pain
somewhat hybrid mass specialti therefor strategi
yet determin could depend strength data
vertex research effort hope identifi opportun specialti
diseas compani hope research effort identifi next cf vertex
focus area valid target assay biomark
creat hope find medicin offer transform benefit could
rapid path registr address diseas major
unmet need littl competit addit hemoglobinopathi diseas current
target vertex research includ antitrypsin defici polycyst
kidney diseas focal segment glomerulosclerosi fsg
defici genet disord may result seriou
respiratori diseas includ prematur emphysema adult liver diseas
patient age roughli patient eu
defici increas risk emphysema liver diseas howev
receiv current standard care protein augment commerci
avail protein augment therapi requir weekli iv infus cost
annual due demand treatment schedul patient complianc
challeng lung liver function declin result under-dos
inadequ treatment addit label avail therapi indic use
patient alreadi develop emphysema mean diseas must progress
patient treat
vertex think amen corrector- base therapeut approach similar
cystic fibrosi caus diseas misfold protein
aggreg liver caus liver diseas approxim patient
transport lung protein typic protect lung
proteas without protein lung suscept damag
confid corrector induc correct fold liver
would reduc liver aggreg permit transport lung vertex
think corrector could effect gene therapi gene therapi would
prevent accumul misfold liver would unlik
treat liver manifest diseas
vertex advanc corrector candid late preclin test
manag think first could move clinic develop late year
earli next could produc proof concept data earli next year
vertex develop phase phase ii clinic develop plan
program although yet disclos nonetheless manag think
proof-of-concept data could gener rel short term studi
mechan corrector would increas amount correctli fold
simpli measur level function blood would provid proof
focal segment glomerulosclerosi scar diseas kidney involv
damag glomeruli vertex disclos much research effort
fsg septemb dinner manag acknowledg program
radar nonetheless vertex made much recent progress
molecul sub nanomolar potenc manag think possibl first
could enter clinic develop could possibl achiev proof-
of-concept rel rapidli chang proteinuria provid verifi biomark
diseas
project produc non-gaap net incom
cash flow gener seemingli pois increas dramat investor
question manag plan deploy capit manag expect use
capit pursu innov expect buy back suffici number
share stop share creep keep share count rel stabl howev
expect major share repurchas declar dividend manag
would rather use capit busi develop supplement intern research
develop pursu program could contribut long term growth
initi phase iib dose-rang studi oral bunionectomi surgeri
obtain addit ex-u reimburs orkambi homozygot patient
advanc addit non-cf pipelin candid clinic
phase ii data inhibitor small fiber neuropathi
result pivot trial tripl combin regimen homozyg het
initi phase ii studi monotherapi cf patient gate mutat
partner releas phase data pimodivir influenza non-hospit patient
file fda approv first tripl regimen
file ema approv first tripl regimen cystic fibrosi
possibl updat merck kgaa oncolog
possibl in-licens partnership extern pipelin asset
advanc addit next-gener corrector develop
fda approv launch first tripl regimen cystic fibrosi
partner releas phase data pimodivir influenza hospit patient
earli
cowen compani
cowen compani
fy dec except per symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling lncome exclud soe exclud soe expens net share share stock option expens cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu two relat product kalydeco
orkambi forecast sale franchis difficult outlook could
alter new safety/efficaci find emerg competit alter medic
treatment paradigm chang pricing/reimburs environ vertex
stock price could also affect chang outlook key pipelin program
includ second gener corrector evalu market potenti
drug yet approv particularli riski
